LL-37 in Antimicrobial Peptide Research

LL-37 is a frequently studied antimicrobial peptide in laboratory research. The compound is a 37-amino-acid peptide derived from the human cathelicidin precursor protein. Researchers examine it in controlled in-vitro models to investigate how peptides interact with lipid membranes. This article provides a research-use-only overview of LL-37, its molecular characteristics, and the experimental systems used to study it.

What Is LL-37?

LL-37 is a short peptide chain made of 37 amino acids. An amino acid is a small molecular building block that joins with other amino acids to form a peptide or protein. The compound belongs to the cathelicidin family. Cathelicidins are a group of antimicrobial peptides produced as precursor proteins and processed to release smaller peptide fragments.

Two molecular features are central to LL-37 research. The first is its net positive charge under commonly studied conditions. This charge comes partly from amino acids such as arginine and lysine. The second is its amphipathic structure. Amphipathic means that different regions of a molecule interact differently with water and fat-like environments. These properties make LL-37 relevant to membrane-interaction research.

The human CAMP gene encodes the cathelicidin precursor protein known as hCAP18. Enzymes process this precursor to release LL-37. The peptide’s name refers to its two initial leucine residues and its total length of 37 amino acids. Leucine is one of the amino acids that make up the peptide sequence.

Researchers examining this compound can consult the LL-37 research peptide page for its product-specific information. The scientific literature also provides background on its molecular structure and classification. A review published in Biochimica et Biophysica Acta discusses LL-37’s structural properties and membrane interactions.

Antimicrobial Peptide Research

An antimicrobial peptide is a short chain of amino acids investigated for its interactions with microorganisms and their membranes. A host-defence peptide is a related term for a peptide examined in the context of an organism’s innate defence systems. LL-37 is described using both terms in scientific literature.

Antimicrobial peptide research often examines how these molecules interact with lipid membranes rather than focusing on a single enzymatic target. A lipid membrane is a thin barrier formed mainly from fat-like molecules that separates a cell’s interior from its surroundings. Researchers use simplified membrane systems to investigate peptide structure, membrane binding, and changes in membrane organisation.

Membrane-Interaction Research

Membrane contact is influenced by electrical charge. Positively charged regions of a peptide can interact with negatively charged phospholipid head groups. Phospholipids are fat-like molecules that form the main structure of many biological membranes. Differences in membrane composition are important experimental variables. Bacterial membranes and mammalian cell membranes differ in their lipid composition and surface properties. Researchers use these differences to compare peptide interactions under defined laboratory conditions.

Several experimental systems support this work:

• Lipid vesicle assays. Vesicles are small, closed spheres made from lipids. They serve as simplified models of biological membranes.
• Supported lipid bilayers. A bilayer is a membrane made of two layers of phospholipids. A supported bilayer rests on a solid surface for imaging and analysis.
• Planar bilayer electrophysiology. This technique measures electrical currents across an artificial membrane. The measurements can help researchers examine changes in membrane permeability.
• Circular dichroism and nuclear magnetic resonance spectroscopy. These analytical techniques provide information about peptide structure and its interactions with surrounding molecules.
• Fluorescence leakage assays. These tests measure the release of a fluorescent dye from lipid vesicles. Dye release provides an indicator of changes in membrane integrity.

Researchers also compare different structural models. The pore model proposes that peptides form channel-like structures in a membrane. The carpet model proposes that peptides accumulate on a membrane surface and may disrupt its organisation. The toroidal model describes a proposed channel structure in which the membrane bends around the opening. These models are interpretations of experimental observations, and their relevance can vary with the peptide and conditions studied.

How LL-37 Is Studied

An in-vitro model is an experiment performed outside a living organism, usually in a laboratory vessel or instrument. These models allow researchers to control variables such as concentration, salt level, pH, and temperature.

Common experimental approaches include:

• Minimum inhibitory concentration assays. These tests estimate the lowest concentration of a compound that prevents visible microbial growth under specified laboratory conditions.
• Membrane permeability assays. These tests use fluorescent probes to measure changes in membrane integrity.
• Biofilm biomass assays. A biofilm is a community of microorganisms attached to a surface and surrounded by a protective matrix. Biomass assays estimate the amount of material present in a laboratory model.
• Time-kill measurements. These experiments track changes in microbial counts across defined sampling intervals.
• Cell culture compatibility assays. These tests use cultured cells and viability indicators to examine cellular responses under specified experimental conditions.

Each method has limitations. Salt concentration, the composition of the culture medium, and other experimental variables can affect measurements. Reporting these conditions is essential when comparing findings across studies.

LL-37 is also examined in cell culture models involving molecular signalling. Cell culture is the growth of cells under controlled laboratory conditions. Researchers may investigate gene transcription, receptor interactions, and changes in signalling markers within these systems.

Cytokine expression assays in thymic peptide research use related analytical approaches. A cytokine is a small signalling protein involved in communication between cells. An assay is a laboratory test designed to measure a specific variable.

Common readouts include messenger RNA levels measured by quantitative polymerase chain reaction (qPCR), protein levels measured by enzyme-linked immunosorbent assay (ELISA), and reporter gene activity. Messenger RNA carries genetic instructions used in protein production. These measurements describe observations in defined experimental systems and should not be interpreted as evidence of clinical outcomes.

Why It Is Studied

LL-37 is of interest in antimicrobial peptide research because its molecular structure provides a framework for examining interactions between peptides and membranes. Researchers can compare structural models, membrane composition, and experimental conditions to investigate how these variables relate to observed molecular behaviour.

Research also examines LL-37 in cell-based systems to characterise its interactions with cellular signalling pathways. These studies involve distinct experimental questions and should be evaluated according to their methods and evidence.

Analytical quality is another important consideration. Mass spectrometry is a technique used to assess molecular mass and support peptide identity verification. High-performance liquid chromatography (HPLC) is a separation method used to assess sample composition and purity. Appropriate analytical documentation helps researchers evaluate the identity and quality of the material used in an experiment.

LL-37 belongs to a wider research area involving thymic peptides. Related topics include [thymic peptides and T-cell differentiation models] and [cytokine expression assays in thymic peptide research]. These areas provide additional context for understanding how researchers investigate peptide-related molecular pathways in controlled laboratory systems.

For Research Use Only

LL-37 research focuses on molecular structure, membrane interactions, and observations from defined in-vitro models. Findings should be interpreted in the context of each study’s methods, limitations, and evidence level. Laboratory observations alone do not establish broader biological effects or demonstrate safety.

For research use only. This content is provided for in-vitro laboratory research purposes. The compounds discussed are not for human consumption and are not approved by the FDA or EMA to prevent, treat, or cure any condition. Introduction into humans or animals is prohibited by law.

References

1. Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmundsson GH. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci USA. 1995;92(1):195-199.
2. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem. 1996;238(2):325-332.
3. Dürr UHN, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta Biomembr. 2006;1758(9):1408-1425.
4. Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012;280(1):22-35.
5. UniProt Consortium. UniProt: the universal protein knowledgebase. Nucleic Acids Res. Entry P49913 (CAMP_HUMAN).
6. Zanetti M. The role of cathelicidins in the innate host defenses of mammals. Curr Issues Mol Biol. 2005;7(2):179-196.
7. Tomasinsig L, Zanetti M. The cathelicidins: structure, function and evolution. Curr Protein Pept Sci. 2005;6(1):23-34.
8. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415(6870):389-395.
9. Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem. 1998;273(6):3718-3724.
10. Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes. Biochem J. 1999;341(Pt 3):501-513.
11. Henzler Wildman KA, Lee DK, Ramamoorthy A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry. 2003;42(21):6545-6558.
12. Porcelli F, Verardi R, Shi L, Henzler-Wildman KA, Ramamoorthy A, Veglia G. NMR structure of the cathelicidin-derived human antimicrobial peptide LL-37 in dodecylphosphocholine micelles. Biochemistry. 2008;47(20):5565-5572.
13. Shai Y. Mode of action of membrane active antimicrobial peptides. Biopolymers. 2002;66(4):236-248.
14. Ludtke SJ, He K, Heller WT, Harroun TA, Yang L, Huang HW. Membrane pores induced by magainin. Biochemistry. 1996;35(43):13723-13728.
15. Wimley WC. Describing the mechanism of antimicrobial peptide action with the interfacial activity model. ACS Chem Biol. 2010;5(10):905-917.
16. Sochacki KA, Barns KJ, Bucki R, Weisshaar JC. Real-time attack on single Escherichia coli cells by the human antimicrobial peptide LL-37. Proc Natl Acad Sci USA. 2011;108(16):E77-E81.
17. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother. 1998;42(9):2206-2214.
18. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. CLSI standard M07.
19. Montal M, Mueller P. Formation of bimolecular membranes from lipid monolayers and a study of their electrical properties. Proc Natl Acad Sci USA. 1972;69(12):3561-3566.
20. Wimley WC, Hristova K. Antimicrobial peptides: successes, challenges and unanswered questions. J Membr Biol. 2011;239(1-2):27-34.
21. Overhage J, Campisano A, Bains M, Torfs ECW, Rehm BHA, Hancock REW. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun. 2008;76(9):4176-4182.
22. Wang G. APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res. 2016;44(D1):D1087-D1093.
23. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock REW. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol. 2002;169(7):3883-3891.
24. Bowdish DME, Davidson DJ, Speert DP, Hancock REW. The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. J Immunol. 2004;172(6):3758-3765.
25. Davidson DJ, Currie AJ, Reid GSD, et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol. 2004;172(2):1146-1156.
26. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009;30(3):131-141.
27. Hancock REW, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24(12):1551-1557.
28. Nijnik A, Hancock R. The roles of cathelicidin LL-37 in immune defenses and novel clinical applications. Curr Opin Hematol. 2009;16(1):41-47.
29. Scott MG, Vreugdenhil ACE, Buurman WA, Hancock REW, Gold MR. Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J Immunol. 2000;164(2):549-553.
30. Rosenfeld Y, Papo N, Shai Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. J Biol Chem. 2006;281(3):1636-1643.
31. Bucki R, Leszczyńska K, Namiot A, Sokołowski W. Cathelicidin LL-37: a multitask antimicrobial peptide. Arch Immunol Ther Exp. 2010;58(1):15-25.
32. Ciornei CD, Sigurdardottir T, Schmidtchen A, Bodelsson M. Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37. Antimicrob Agents Chemother. 2005;49(7):2845-2850.